CMPX NASDAQ
Credit Risk of going bust: higher than 85% of companies Debt: 6.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 98%), Compass Therapeutics, Inc. would be worth roughly what it owes.
Total debt $9.6M against a stock market value of $134.6M.
Distance to default 2.17 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.8M (short-term plus half of long-term), stock volatility 126.6%; Altman Z'' 2.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Boston, MA 02135
US
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lerner Neil | P-Purchase | 20,000 | $0.92 | 2026-10-01 |
| Lerner Neil | P-Purchase | 2,500 | $1.14 | 2026-09-24 |
| Lerner Neil | P-Purchase | 15,000 | $1.89 | 2026-04-29 |
| Anderman Jonathan | P-Purchase | 25,000 | $1.89 | 2026-04-29 |
| Anderman Jonathan | A-Award | 25,000 | $1.89 | 2026-04-29 |